Wealth Management Associates’s Arbutus Biopharma ABUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $324K | Buy |
104,920
+8,500
| +9% | +$26.3K | 0.13% | 147 |
|
|
2025
Q1 | $337K | Buy |
96,420
+35,400
| +58% | +$124K | 0.14% | 133 |
|
|
2024
Q4 | $200K | Buy |
61,020
+6,500
| +12% | +$21.3K | 0.09% | 199 |
|
|
2024
Q3 | $210K | Buy |
54,520
+4,700
| +9% | +$18.1K | 0.09% | 195 |
|
|
2024
Q2 | $154K | Hold |
49,820
| – | – | 0.07% | 196 |
|
|
2024
Q1 | $154K | Buy |
49,820
+1,800
| +4% | +$5.56K | 0.07% | 196 |
|
|
2023
Q4 | $120K | Sell |
48,020
-6,600
| -12% | -$16.5K | 0.06% | 195 |
|
|
2023
Q3 | $111K | Buy |
54,620
+5,000
| +10% | +$10.2K | 0.06% | 186 |
|
|
2023
Q2 | $114K | Hold |
49,620
| – | – | 0.06% | 185 |
|
|
2023
Q1 | $150K | Buy |
49,620
+350
| +0.7% | +$1.06K | 0.09% | 185 |
|
|
2022
Q4 | $115K | Buy |
49,270
+8,400
| +21% | +$19.6K | 0.08% | 181 |
|
|
2022
Q3 | $78.1K | Buy |
40,870
+11,200
| +38% | +$21.4K | 0.06% | 172 |
|
|
2022
Q2 | $80.4K | Buy |
29,670
+7,500
| +34% | +$20.3K | 0.05% | 173 |
|
|
2022
Q1 | $66.1K | Buy |
22,170
+3,600
| +19% | +$10.7K | 0.04% | 186 |
|
|
2021
Q4 | $72.2K | Buy |
18,570
+1,800
| +11% | +$7K | 0.04% | 195 |
|
|
2021
Q3 | $71.9K | Sell |
16,770
-700
| -4% | -$3K | 0.04% | 192 |
|
|
2021
Q2 | $52.9K | Sell |
17,470
-11,700
| -40% | -$35.5K | 0.03% | 197 |
|
|
2021
Q1 | $97.1K | Sell |
29,170
-2,400
| -8% | -$7.99K | 0.06% | 186 |
|
|
2020
Q4 | $112K | Buy |
+31,570
| New | +$112K | 0.07% | 177 |
|